Date |
Title |
|
02/11/19 |
Akorn to Report Fourth Quarter and Full Year 2018 Results
LAKE FOREST, Ill. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, February 28, 2019 outlining the fourth quarter and full year 2018 results.
|
|
01/28/19 |
Akorn Announces New Executive and Board Appointments
LAKE FOREST, Ill. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), today announced that it has appointed a new executive team member and two new board members. Christopher C. Young joins Akorn as Executive Vice President, Global Operations reporting to Douglas Boothe , President &
|
|
01/09/19 |
Akorn Receives FDA Warning Letter
LAKE FOREST, Ill. , Jan. 09, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter, dated January 4 , from the U.S. Food and Drug Administration ( FDA ) related to an inspection of its Decatur, Illinois
|
|
01/08/19 |
Akorn Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LAKE FOREST, Ill. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ: AKRX), today announced that Akorn granted an inducement equity award in accordance with Nasdaq Listing Rule 5635(c)(4) pursuant to an employment arrangement with Akorn’s newly appointed President and Chief Executive Officer
|
|
|